The core of ENDRA's business revolves around its proprietary Thermo Acoustic Enhanced UltraSound (TAEUS) technology. This innovative platform utilizes thermo-acoustic principles to generate high-resolution images, offering a cost-effective and non-invasive alternative to existing imaging modalities like MRI. Research and development efforts are focused on enhancing the sensitivity and specificity of TAEUS for various applications, including nonalcoholic fatty liver disease (NAFLD) assessment, temperature monitoring during thermoablative surgery, and vascular imaging. The technology is being developed to provide clinicians with real-time, quantitative data to improve patient outcomes. Market positioning emphasizes the advantages of TAEUS, such as lower cost and improved accessibility compared to traditional methods. Future opportunities include expanding the applications of TAEUS to other disease areas and securing regulatory approvals for broader clinical use. Clinical trials and partnerships with pharmaceutical companies are crucial for validating the technology and driving market adoption. The company is actively collaborating with GE Healthcare and other partners to advance the development and commercialization of TAEUS.